Schizophrenia Drugs
APAC · 1 shared keyword
APAC Contraceptive Innovations Market Industry Trends and Forecast to 2034: Segmented by (Product, Hormone, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
APAC · 2024–2034 · estimates
Market Dashboard
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Estimate 2024
$825.0 Mn
Estimated value
Estimate 2025
$885.3 Mn
18.8% of the global market
Projected 2034
$1.67 Bn 88.5%
Adds $783.8 Mn over 9 forecast years
CAGR 2025–2034
7.3%
Faster than 27% of 180 Pharmaceuticals markets here
- APAC is 18.76% of the global market.
- Among regions, the largest is North America at $2.11 Bn.
- Fastest growing: Africa at 7.8% a year.
- APAC ranks 3rd of 6 by size among regions.
Market size projection
APACSource: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$783.8 Mn total, 2026–2034
Year-by-year market size, 2024–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $825.0 Mn | — | — |
| 2025 (base) | $885.3 Mn | +$60.2 Mn | — |
| 2026 (forecast) | $949.9 Mn | +$64.6 Mn | +7.3% |
| 2027 (forecast) | $1.02 Bn | +$69.3 Mn | +15.1% |
| 2028 (forecast) | $1.09 Bn | +$74.4 Mn | +23.5% |
| 2029 (forecast) | $1.17 Bn | +$79.8 Mn | +32.6% |
| 2030 (forecast) | $1.26 Bn | +$85.7 Mn | +42.2% |
| 2031 (forecast) | $1.35 Bn | +$91.9 Mn | +52.6% |
| 2032 (forecast) | $1.45 Bn | +$98.6 Mn | +63.8% |
| 2033 (forecast) | $1.56 Bn | +$105.8 Mn | +75.7% |
| 2034 (forecast) | $1.67 Bn | +$113.6 Mn | +88.5% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Same market worldwide
By geography
- Global $4.72 Bn
- North America $2.11 Bn
-
US
$1.88 Bn
- Europe $895.6 Mn
- APAC (this report) $885.3 Mn
-
Canada
$384.9 Mn
-
China
$350.4 Mn
-
Japan
$262.9 Mn
- Latin America $227.1 Mn
- Middle East $177.7 Mn
-
Germany
$149.5 Mn
-
France
$122.6 Mn
-
UK
$109.2 Mn
-
Brazil
$105.8 Mn
-
Italy
$100.1 Mn
-
Ecuador
$101.1 Mn
-
Spain
$84.7 Mn
-
India
$86.5 Mn
-
Saudi Arabia
$74.9 Mn
-
Mexico
$72.6 Mn
- Africa $70.3 Mn
-
Australia
$66.1 Mn
-
New Zealand
$46.7 Mn
-
Russia
$45.8 Mn
-
South Africa
$31.0 Mn
-
UAE
$27.3 Mn
-
Egypt
$15.4 Mn
-
Philippines
$9.8 Mn
-
Malaysia
$8.4 Mn
-
Hong Kong
$7.0 Mn
-
Thailand
$6.4 Mn
-
Singapore
$6.3 Mn
-
Kenya
$3.1 Mn
The APAC Contraceptive Innovations Market Analysis Executive Summary
Contraceptive innovations are newer birth-control options such as hormone-free gels, long-acting injectables, vaginal rings and over-the-counter pills.
Key segments of the contraceptive Innovations market include product (Over-the-Counter Pills, Long-Acting Injectables and Vaginal Rings) and hormone (Hormonal and Non-Hormonal).
APAC Contraceptive Innovations Market Dynamics
Market Growth Drivers
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the contraceptive Innovations market. New products designed around women's biology and digital care are improving access.
Opportunity
Femtech, personalised care and new treatments for under-served conditions open strong growth for the contraceptive Innovations market, especially as employers and payers add women's health benefits.
Market Restraints
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the contraceptive Innovations market.
Competitive Landscape for Contraceptive Innovations Market in APAC
The contraceptive Innovations market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Key Players
Healthcare Policies and Regulatory Landscape for Contraceptive Innovations Market in APAC
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for contraceptive Innovations. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
From our blog
Women's Health Supplements: A Growing FocusAnaemia affects about half a billion women worldwide, and folic acid before pregnancy prevents serious birth…
Breast Cancer Screening and Diagnosis: Closing the GapBreast cancer is the most common cancer in women worldwide. Finding it early saves lives, but access to…
Fertility Services: Rising Demand and Access GapsAbout 1 in 6 adults experience infertility. In many countries one IVF cycle costs more than a year's income.